Our history

1971-1973

Creation of IRE and first constructions.

1971-1973
1971-1973
1971-1973

1973-1978

  • First transfer of activities to Fleurus.
  • Construction of six buildings in record times.
  • First production runs of 131I and 99Mo.
  • Creation of a radioimmunology department.
  • Creation of a 60Co irradiation treatment unit.
  • Sterilization of medical equipment.
  • First production of 123I.
1973-1978
1973-1978
1973-1978
1973-1978
1973-1978

1978-1991

  • Creation of the production unit of 192Ir, for sealed sources.
  • Construction of the first cyclotron.
  • Pharmaceutical approval of the company.
  • Creation of molecules marked with tritium and 14C.
  • Production of tritiated thymidine.
  • Production of 85Kr fire detectors.
  • Production of 60Co discs.
  • Production of 192Ir industrial radiography equipment.
  • Development of injectable radioactive preparations based on 59Fe, 47Ca, 197Hg and 85Sr, as well as 192Ir sutures and pins (brachytherapy).
  • Creation of the concept for a repetitive elution 99mTc dry generator.
  • Creation of the transport subsidiary company TRANSRAD.
1978-1991
1978-1991
1978-1991
1978-1991
1978-1991
1978-1991
1978-1991

1991-2008

  • Impact of Regionalization on some of the IRE’s activities:
    • Sale of the radiopharmaceutical product lines to the NORDION group.
    • Divestment of the sterilization and radioimmunology testing activities.
    • Refocusing of the IRE activity on the core businesses with the production of the medical radioisotopes 99Mo, 131I and 133Xe.
  • Major investments in the context of the redeployment of radiopharmaceutical activities.
  • Development of equipment for the remote monitoring of environmental radioactivity and radiological monitoring missions within the territory.
  • Support by IRE of the development of the company IBA, which also invested in the Fleurus site (R&D activities supported by a prototype 14 MeV SE cyclotron).
1991-2008
1991-2008
1991-2008
1991-2008

2008-2010

  • Important expansion of international commercial activities. In addition to the European market, IRE takes a significant role as a major stakeholder in North America, Asia, and the Middle East. This achievement provided IRE with a leadership position in the production of 99Mo and 131I.
  • Substantial investments in the renovation of installations in terms of safety, security and quality.
2008-2010
2008-2010
2008-2010
2008-2010
2008-2010
2008-2010

2010

  • Creation of the IRE ELiT subsidiary.
  • New development in radiopharmaceutical activities in the diagnostic and therapy sectors (90Y, 188Re, 68Ga, etc.).
  • Major consultancy contracts worldwide (European Commission, IAEA, etc.).
2010
2010
2010
2010

2010-...

  • New IRE communication policy in relation to its environment.
  • Growth in revenue from 2010 to 2015: 140%.
  • Growth in headcount from 2010 to 2015: 53%.
  • Launch of research partnerships worldwide.
  • First partnership with Belgian universities in the field of medical research.
  • Major participation in the NEA/OECD High-Level Group (HLG) on the Security of Supply of Medical Radioisotopes.
  • Important IRE role in AIPES (Association of Imaging Producers & Equipment Suppliers).
  • Participation in the BioWin Health Cluster of the Walloon region (southern part of Belgium).
2010-...
2010-...
2010-...
IRE - Institute for Radioelements IRE Elit - Environement and lifescience Technology